| Issue Date |
Title |
Author(s) |
| Mar-2021 |
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial |
Zhou, Caicun;Chen, Gongyan;Huang, Yunchao;Zhou, Jianying;Lin, LiZhu;Feng, Jifeng;Wang, Zhehai;Shu, Yongqian;Shi, Jianhua;Hu, Yi;Wang, QiMing;Cheng, Ying;Wu, Fengying;Chen, Jianhua;Lin, Xiaoyan;Wang, Yongsheng;Huang, Jianan;Cui, Jiuwei;Cao, Lejie;Liu, Yunpeng;Zhang, Yiping;Pan, Yueyin;Zhao, Jun;Wang, LiPing;Chang, Jianhua;Chen, Qun;Ren, Xiubao;Zhang, Wei;Fan, Yun;He, Zhiyong;Fang, Jian;Gu, Kangsheng;Dong, XiaoRong;Zhang, Tao;Shi, Wei;Zou, Jianjun |
| Jul-2021 |
ctDNA analysis in the savolitinib phase II study in Non-Small Cell Lung Cancer (NSCLC) patients (pts) harboring MET exon 14 skipping alterations (METex14). |
Yu, Yongfeng;Ren, Yongxin;Fang, Jian;Cao, Lejie;Liang, Zongan;Guo, Qisen;Han, Sen;Ji, Zimei;Wang, Ye;Sun, Yulan;Chen, Yuan;Li, Xingya;Xu, Hua;Zhou, Jianying;Jiang, Liyan;Cheng, Ying;Han, Zhigang;Shi, Jianhua;Chen, Gongyan;Ma, Rui;Fan, Yun;Sun, Sanyuan;Jiao, Longxian;Jia, Xiaoyun;Wang, Linfang;Lu, Puhan;Li, Jing;Xu, Qian;Luo, Xian;Su, Weiguo;Lu, Shun |
| Jul-2021 |
D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156). |
Lu, Shun;Zhang, Yiping;Zhang, Guojun;Zhou, Jianying;Cang, Shundong;Cheng, Ying;Wu, Gang;Cao, Peiguo;Lv, Dongqing;Jin, Xiangming;Jian, Hong;Chen, Chengshui;Jiang, Guanming;Tian, Panwen;Wang, Kai;Zhao, Hui;Chen, Gongyan;Chen, Qun;Ding, Cuimin;Yang, Junquan;Guo, Renhua;Sun, Guoping;Wang, Bin;Jiang, Liyan;Zhuang, Wu;Liu, Zhe;Fang, Jian;Liu, Yunpeng;Zhang, Jian;Chen, Jun;Pan, Yueyin;Yu, Qitao;Zhao, Min;Cui, Jiuwei;Li, Dianming;Yi, Tienan;Yu, Zhuang;Yang, Yan;Zhang, Yan;Zhi, Xiuyi;Huang, Yunchao;Wu, Rong;Chen, Liangan;Zang, Aimin;Cao, Lejie;Li, Qingshan;Li, Xiaoling;Song, Yong;Wang, Donglin;Zhang, Shucai |
| Aug-2021 |
Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study |
Ai, Xinghao;Pan, Yueyin;Shi, Jianhua;Yang, Nong;Liu, Chunling;Zhou, Jianying;Zhang, Xiaodong;Dong, Xiaorong;He, Jianxing;Li, Xiaoling;Chen, Gongyan;Li, Xingya;Zhang, Helong;Liao, Wangjun;Zhang, Yiping;Ma, Zhiyong;Jiang, Liyan;Cui, Jiuwei;Hu, Chunhong;Wang, Wei;Huang, Cheng;Zhao, Jun;Ding, Cuimin;Hu, Xiaohua;Wang, Kai;Gao, Beili;Song, Yong;Liu, Xiaoqing;Xiong, Jianping;Liu, Anwen;Li, Junling;Liu, Zhe;Li, Yinyin;Wang, Mengzhao;Zhang, Biao;Zhang, Dan;Lu, Shun |
| Oct-2020 |
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11) |
Yang, Yunpeng;Wang, Zhehai;Fang, Jian;Yu, Qitao;Han, Baohui;Cang, Shundong;Chen, Gongyan;Mei, Xiaodong;Yang, Zhixiong;Ma, Rui;Bi, Minghong;Ren, Xiubao;Zhou, Jianying;Li, Baolan;Song, Yong;Feng, Jifeng;Li, Juan;He, Zhiyong;Zhou, Rui;Li, Weimin;Lu, You;Wang, Yingyi;Wang, Lijun;Yang, Nong;Zhang, Yan;Yu, Zhuang;Zhao, Yanqiu;Xie, Conghua;Cheng, Ying;Zhou, Hui;Wang, Shuyan;Zhu, Donglei;Zhang, Wen;Zhang, Li |
| 2011 |
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study |
Zhou, Caicun;Wu, Yi-Long;Chen, Gongyan;Feng, Jifeng;Liu, Xiao-Qing;Wang, Changli;Zhang, Shucai;Wang, Jie;Zhou, Songwen;Ren, Shengxiang;Lu, Shun;Zhang, Li;Hu, Chengping;Hu, Chunhong;Luo, Yi;Chen, Lei;Ye, Ming;Huang, Jianan;Zhi, Xiuyi;Zhang, Yiping;Xiu, Qingyu;Ma, Jun;Zhang, Li;You, Changxuan |
| 2015 |
First-Line Icotinib Versus Cisplatine/Pemetrexed Plus Pemetrexed Maintenance in Advanced NSCLC Patients with EGFR Mutation |
Shi, Yuankai;Wang, Lin;Han, Baohui;Li, Wei;Yu, Ping;Liu, Yunpeng;Ding, Cuimin;Song, Xia;Ma, Zhiyong;Ren, Xinling;Feng, Jifeng;Zhang, Helong;Chen, Gongyan;Wu, Ning;Han, Xiaohong;Yao, Chen;Song, Yong;Zhang, Shucai;Ding, Lieming;Tan, Fenlai |
| Nov-2022 |
Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy |
Wu, Fengying;Jiang, Tao;Chen, Gongyan;Huang, Yunchao;Zhou, Jianying;Lin, Lizhu;Feng, Jifeng;Wang, Zhehai;Shu, Yongqian;Shi, Jianhua;Hu, Yi;Wang, Qiming;Cheng, Ying;Chen, Jianhua;Lin, Xiaoyan;Wang, Yongsheng;Huang, Jianan;Cui, Jiuwei;Cao, Lejie;Liu, Yunpeng;Zhang, Yiping;Pan, Yueyin;Zhao, Jun;Wang, LiPing;Chang, Jianhua;Chen, Qun;Ren, Xiubao;Zhang, Wei;Fan, Yun;He, Zhiyong;Fang, Jian;Gu, Kangsheng;Dong, Xiaorong;Zhang, Tao;Shi, Wei;Zou, Jianjun;Bai, Xuejuan;Ren, Shengxiang;Zhou, Caicun |
| 2015 |
An open-label, randomized, multicenter, phase III study of S-1 and cisplatin versus docetaxel and cisplatin in patients with untreated advanced non-small-cell lung cancer. |
He, Jianxing;Shi, Yuankai;Chang, Jianhua;Wang, Mengzhao;Han, Baohui;Liu, Xiaoqing;Chen, Gongyan;Zhou, Caicun;Liu, Jiwei;Pan, Hongming;Huang, Cheng;Zhang, Shucai;Feng, Jifeng;Lin, Xiaoyan;Wang, Jie;Huang, Jianjin;Li, Fang;Qin, Shukui;Wang, Zhehai;Wang, Liwei |
| 2015 |
An open-label, randomized, multicenter, phase III study of S-1 and cisplatin versus docetaxel and cisplatin in patients with untreated advanced non-small-cell lung cancer. |
He, Jianxing;Shi, Yuankai;Chang, Jianhua;Wang, Mengzhao;Han, Baohui;Liu, Xiaoqing;Chen, Gongyan;Zhou, Caicun;Liu, Jiwei;Pan, Hongming;Huang, Cheng;Zhang, Shucai;Feng, Jifeng;Lin, Xiaoyan;Wang, Jie;Huang, Jianjin;Li, Fang;Qin, Shukui;Wang, Zhehai;Wang, Liwei |
| 2012 |
Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCL |
Zhou, Caicun;Wu, Yi Long;Liu, Xiaoqing;Wang, Changli;Chen, Gongyan;Feng, Ji Feng;Zhang, Shucai;Wang, Jie;Zhou, Songwen;Ren, Shengxiang;Lu, Shun;Zhang, Li;Hu, Cheng-ping;Luo, Yi;Chen, Lei;Ye, Ming;Huang, Jianan;Zhi, Xiuyi;Zhang, Yiping;Xiu, Qingyu |
| Aug-2020 |
A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study |
Lu, Shun;Chen, Gongyan;Sun, Yuping;Sun, Sanyuan;Chang, Jianhua;Yao, Yu;Chen, Zhendong;Ye, Feng;Lu, Junguo;Shi, Jianhua;He, Jianxing;Liu, Xiaoqing;Zhang, Yiping;Liu, Zhihua;Fang, Jian;Cheng, Ying;Hu, Chunhong;Mao, Weidong;Hu, Yanping;Gong, Youling;Shan, Li;Yang, Zhixiong;Song, Yong;Li, Wei;Bai, Chong;Wang, Buhai;Ma, Rui;Zheng, Zhendong;Liu, Mingfang;Jie, Zhijun;Cao, Lejie;Liao, Wangjun;Pan, Hongming;Huang, Dongning;Chen, Yuan;Yang, Jinji;Qin, Shukui;Ma, Shenglin;Liang, Li;Liu, Zhe;Zhou, Jianying;Tao, Min;Huang, Yijiang;Qiu, Feng;Huang, Yunchao;Guan, Sha;Peng, Mengye;Su, Weiguo |
| 2019 |
Preliminary efficacy and safety results of savolitinib treating patients with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations |
Lu, Shun;Fang, Jian;Cao, Lejie;Li, Xingya;Guo, Qisen;Zhou, Jianying;Cheng, Ying;Jiang, Liyan;Chen, Yuan;Zhang, Helong;Liang, Zongan;Zhang, Xin;Wu, Biao;Shi, Jianhua;Xu, Hua;Huang, Jianjin;Yang, Zhixiong;Zeng, Shan;Hu, Yanping;Zhang, Xiaodong;Wu, Jingxun;Chen, Gongyan;Yang, Nong;Zhang, Longzhen;Fu, Yinjia;Li, Jing;Wang, Linfang;Ren, Yongxin;Su, Weiguo |
| 20-Aug-2020 |
Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study |
Zhou, Caicun;Li, Xingya;Wang, Qiming;Gao, Guanghui;Zhang, Yiping;Chen, Jianhua;Shu, Yongqian;Hu, Yanping;Fan, Yun;Fang, Jian;Chen, Gongyan;Zhao, Jun;He, Jianxing;Wu, Fengying;Zou, Jianjun;Zhu, Xiaoyu;Lin, Xiang |
| Dec-2021 |
Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study |
Yang, Yunpeng;Sun, Jiya;Wang, Zhehai;Fang, Jian;Yu, Qitao;Han, Baohui;Cang, Shundong;Chen, Gongyan;Mei, Xiaodong;Yang, Zhixiong;Ma, Rui;Bi, Minghong;Ren, Xiubao;Zhou, Jianying;Li, Baolan;Song, Yong;Feng, Jifeng;Li, Juan;He, Zhiyong;Zhou, Rui;Li, Weimin;Lu, You;Zhou, Hui;Wang, Shuyan;Sun, Luyao;Puig, Oscar;Mancao, Christoph;Peng, Bo;Fang, Wenfeng;Xu, Wei;Zhang, Li |
